Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11)

In vitro studies suggest cryptotanshinone could help treat Noonan syndrome and some cancers. Noonan syndrome and other cancers are caused by activating mutations in SHP-2. In vitro, cryptotanshinone directly bound and selectively inhibited SHP-2. In mouse myeloid progenitor cells and human cancer cells expressing SHP-2 with an activating mutation, cryptotanshinone inhibited SHP-2-mediated cell signaling and decreased cell growth compared with vehicle. Next steps could include developing analogs for preclinical testing.
Aarden Pharmaceuticals Inc.'s SHP-2 inhibitor,
Il-B08, is in preclinical testing to treat cancers.

SciBX 6(36); doi:10.1038/scibx.2013.991
Published online Sept. 19, 2013

Patent and licensing status unavailable

Liu, W. et al. J. Med. Chem.; published online Aug. 19, 2013;
doi:10.1021/jm400474r
Contact: Cheng-Kui Qu, Case Western Reserve University, Cleveland, Ohio
e-mail:

cxq6@case.edu